OBJECTIVES: The purpose of this analysis was to assess in patients with type 2 diabetes and stable coronary artery disease (CAD) whether the risk of all-cause mortality and cardiovascular events varied according to the presence or absence of angina and angina equivalent symptoms. BACKGROUND: Data on the prognostic value of symptoms in these patients are limited. METHODS: Post-hoc analysis was performed in 2,364 patients with type 2 diabetes and documented CAD enrolled in the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial to determine the occurrence of death and composite of death, myocardial infarction, and stroke during a 5-year follow-up according to cardiac symptoms at baseline. RESULTS: There were 1,434 patients with angina (A), 506 with angina equivalents (E), and 424 with neither of these (N). The cumulative death rates (total 316) were 12% in A, 14% in E, and 10% in N (p = 0.3), and cardiovascular composite rates (total 548) were 24% in A, 24% in E, and 21% in N (p = 0.5). Compared with N, the hazard ratios adjusted for confounders were not different for death in A (1.11; 99% CI: 0.81 to 1.53) and E (1.17; 99% CI: 0.81 to 1.68) or for cardiovascular events in A (1.17; 99% CI: 0.92 to 1.50) and E (1.11; 99% CI: 0.84 to 1.48). CONCLUSIONS: Whatever their symptom status, patients with type 2 diabetes and stable CAD were at similar risk of cardiovascular events and death. These findings suggest that these patients may be similarly managed in terms of risk stratification and preventive therapies. (Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D]; NCT00006305).
RCT Entities:
OBJECTIVES: The purpose of this analysis was to assess in patients with type 2 diabetes and stable coronary artery disease (CAD) whether the risk of all-cause mortality and cardiovascular events varied according to the presence or absence of angina and angina equivalent symptoms. BACKGROUND: Data on the prognostic value of symptoms in these patients are limited. METHODS: Post-hoc analysis was performed in 2,364 patients with type 2 diabetes and documented CAD enrolled in the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial to determine the occurrence of death and composite of death, myocardial infarction, and stroke during a 5-year follow-up according to cardiac symptoms at baseline. RESULTS: There were 1,434 patients with angina (A), 506 with angina equivalents (E), and 424 with neither of these (N). The cumulative death rates (total 316) were 12% in A, 14% in E, and 10% in N (p = 0.3), and cardiovascular composite rates (total 548) were 24% in A, 24% in E, and 21% in N (p = 0.5). Compared with N, the hazard ratios adjusted for confounders were not different for death in A (1.11; 99% CI: 0.81 to 1.53) and E (1.17; 99% CI: 0.81 to 1.68) or for cardiovascular events in A (1.17; 99% CI: 0.92 to 1.50) and E (1.11; 99% CI: 0.84 to 1.48). CONCLUSIONS: Whatever their symptom status, patients with type 2 diabetes and stable CAD were at similar risk of cardiovascular events and death. These findings suggest that these patients may be similarly managed in terms of risk stratification and preventive therapies. (Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D]; NCT00006305).
Authors: Michael J Zellweger; Rory Hachamovitch; Xingping Kang; Sean W Hayes; John D Friedman; Guido Germano; Matthias E Pfisterer; Daniel S Berman Journal: Eur Heart J Date: 2004-04 Impact factor: 29.983
Authors: Maria Mori Brooks; Robert L Frye; Saul Genuth; Katherine M Detre; Richard Nesto; Burton E Sobel; Sheryl F Kelsey; Trevor J Orchard Journal: Am J Cardiol Date: 2006-04-17 Impact factor: 2.778
Authors: S D Rosen; E Paulesu; P Nihoyannopoulos; D Tousoulis; R S Frackowiak; C D Frith; T Jones; P G Camici Journal: Ann Intern Med Date: 1996-06-01 Impact factor: 25.391
Authors: Michael J Zellweger; Markus Weinbacher; Andreas W Zutter; Raban V Jeger; Jan Mueller-Brand; Christoph Kaiser; Peter T Buser; Matthias E Pfisterer Journal: J Am Coll Cardiol Date: 2003-07-02 Impact factor: 24.094
Authors: Harry Hemingway; Natalie K Fitzpatrick; Shamini Gnani; Gene Feder; Neil Walker; Angela M Crook; Patrick Magee; Adam Timmis Journal: Can J Cardiol Date: 2004-03-01 Impact factor: 5.223
Authors: D A Weiner; T J Ryan; L Parsons; L D Fisher; B R Chaitman; L T Sheffield; F E Tristani Journal: Am J Cardiol Date: 1991-09-15 Impact factor: 2.778
Authors: David E Winchester; Rhonda M Cooper-Dehoff; Yan Gong; Eileen M Handberg; Carl J Pepine Journal: Clin Cardiol Date: 2013-05-29 Impact factor: 2.882
Authors: Marina Gradišer; Dario Dilber; Jasna Cmrečnjak; Branko Ostrički; Ines Bilić-Ćurčić Journal: Int J Environ Res Public Health Date: 2015-01-27 Impact factor: 3.390
Authors: Se Hun Kang; Hyo In Choi; Young Hak Kim; Eun Young Lee; Jung Min Ahn; Seungbong Han; Pil Hyung Lee; Jae Hyung Roh; Sung Han Yun; Duk Woo Park; Soo Jin Kang; Seung Whan Lee; Cheol Whan Lee; Dae Hyuk Moon; Seong Wook Park; Seung Jung Park Journal: Yonsei Med J Date: 2017-09 Impact factor: 2.759
Authors: Alon Eisen; Deepak L Bhatt; P Gabriel Steg; Kim A Eagle; Shinya Goto; Jianping Guo; Sidney C Smith; E Magnus Ohman; Benjamin M Scirica Journal: J Am Heart Assoc Date: 2016-09-28 Impact factor: 5.501